Hints and tips:
Related Special Reports
...Another option might be to use public development partnerships, such as the model followed by the Medicines for Malaria Venture (MMV)....
...MMV, a public-private partnership, has a portfolio of eight new drugs in clinical development....
...Mam is backed by partners including Transaid, an aid organisation that focuses on the provision of sustainable forms of transport, and the Medicines for Malaria Venture (MMV), a Swiss foundation....
...Novartis, the Swiss drug company, has developed KAF156 in collaboration with Medicines for Malaria Venture (MMV), a public-private partnership, and charities including the Wellcome Trust and Gates Foundation...
...Novartis and MMV have two treatments in earlier phase II trials....
...The MMV is not relying solely on big pharmaceuticals groups....
...MMV and pharmaceutical company partners provide the new drug compounds, which are tested by QIMR....
...Timothy Wells, chief scientific officer at MMV, said the compound “holds great promise”....
...While sharing much of its expertise with MMV, the company is developing on its own the most advanced compound – codenamed 609 – partly because “MMV is not particularly swimming in money” and it hopes to...
...One such alteration, with MMV’s support, was a soluble cherry-flavoured version designed for children, those most affected by malaria but who often found the original drug difficult to swallow....
...MMV hopes it can be offered as a single dose cure. Tim Wells, chief scientific officer of MMV, says: “We are quietly hopeful that we can have this non-artemisinin drug ready by 2015.”...
...Novartis, one manufacturer of ACTs (artemisinin combination therapies - the current preferred treatment) that are pre-qualified by the WHO teamed up with Medicines for Malaria Venture (MMV) to launch a sweet-tasting...
...“It’s the ultimate proof of principle for PDPs,” says Chris Hentschel, head of MMV....
...MMV and its Korean and Italian pharma partners are now preparing two new ACTs for regulatory approval. Both of the drugs originated in China....
...The work of MMV and similar PPPs are beginning to deliver promising results....
...In a brief e-mail, she pointed out that MMV is one of several partnerships between drug firms and public agencies set up in recent years to fund the development of effective and affordable drugs for diseases...
International Edition